Clinical trials
Trastuzumab clinical trials
Below are recruiting trastuzumab clinical trials, each written for real people, not researchers. We’re tracking 234 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07441460RecruitingPhase 3
KN026 plus HB1801 after surgery for HER2-positive breast cancer
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06837792RecruitingPhase 2
T-DXd vs hormone therapy for HER2-low advanced breast cancer
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
SeoulAges 19 years+ - NCT05982678RecruitingPhase 2
Study of a drug for breast cancer that has spread to a few spots
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
AmsterdamAges 18 years+ - NCT06486883RecruitingPhase 2
T-DXd vs CDK4/6i plus hormone therapy for advanced HR-positive, HER2-low breast cancer
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
GrazAges 18 years+ - NCT06525298RecruitingPhase 1/Phase 2
Study of EIS-12656 for solid tumors with DNA repair defects
This trial tests a new drug, EIS-12656, alone or with other treatments, for solid tumors that have specific DNA repair problems called homologous recombination deficiency. It may be an option if your cancer has not responded to prior treatments.
Houston, TexasAges 18 years+ - NCT06102824RecruitingPhase 2
Organoid-guided treatment for advanced breast cancer
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
Guangzhou, GuangdongAges 18–80 - NCT07009184RecruitingEarly Phase 1
Imaging study for HER2-positive cancers using TGW211
This trial tests whether a new imaging agent called TGW211 can help doctors see HER2-positive cancers more clearly on scans. It may lead to better ways to track these cancers in the future.
Nijmegen, GelderlandAges 18 years+ - NCT07407920RecruitingPhase 2
Optimizing treatment for early HER2+ and triple-negative breast cancer
This trial aims to see if patients who had a complete response to chemo before surgery can safely stop or reduce their targeted therapy afterward. It includes people with early-stage HER2-positive or triple-negative breast cancer who had no cancer cells left in the tissue removed at surgery (a pathological complete response).
Houston, TexasAges 18 years+ - NCT06767436Recruiting
Real-world study of Enhertu for advanced gastric cancer
This study looks at how well the drug Trastuzumab Deruxtecan works and how safe it is in real-world patients with advanced stomach or gastroesophageal cancer whose tumors are HER2-positive. The goal is to gather more information beyond what was learned in clinical trials.
Seoul, SeoulAges 19 years+ - NCT07726433RecruitingPhase 2
Preventing nausea from Trastuzumab Rezetecan with two anti-nausea drugs
This trial tests whether a combination of two anti-nausea drugs (fosrolapitant and palonosetron) can better prevent nausea and vomiting caused by Trastuzumab Rezetecan. If you are starting this cancer treatment, you may be able to join.
TianjinAges 18 years+ - NCT07047365RecruitingPhase 3
New drug for HER2-positive advanced breast cancer
This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.
Bengbu, AnhuiAges 18–75 - NCT07739511RecruitingPhase 1/Phase 2
Oral paclitaxel for HER2-positive breast cancer before surgery
This trial tests an oral form of paclitaxel combined with standard HER2 therapy given before surgery for HER2-positive breast cancer. It aims to find the best dose and see how well it works.
Guiyang, GuizhouAges 18–70 - NCT06680596Enrolling by invitationPhase 2
Blood test to find T-DXd candidates for breast cancer
This trial uses a blood test to look for tumor DNA in women with a certain type of advanced breast cancer (HR-positive, HER2-low). If the DNA doesn't disappear after starting standard hormone therapy with a CDK4/6 inhibitor, participants may be switched to a targeted drug called T-DXd (trastuzumab deruxtecan).
AmiensAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Birmingham, AlabamaAges 18–130 - NCT07708194RecruitingPhase 1/Phase 2
Entinostat plus pyrotinib and hormone therapy for advanced breast cancer
This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07102381RecruitingPhase 2
Zanidatamab plus chemo before surgery for HER2+ breast cancer
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
Long Beach, CaliforniaAges 18 years+ - NCT03424005RecruitingPhase 1/Phase 2
Testing new drug combinations for advanced breast cancer
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
Duarte, CaliforniaAges 18 years+ - NCT03297606RecruitingPhase 2
Match your tumor test to a targeted cancer drug
This trial studies whether giving a targeted cancer medicine based on tumor genetic/protein test results can help people with advanced, incurable cancers live longer. You may be eligible if your cancer has a “potentially actionable” change on testing and you meet health and follow-up requirements.
Edmonton, AlbertaAges 18 years+ - NCT03803553RecruitingPhase 3
Testing blood tumor DNA treatment after stage III colon surgery
This trial studies how to find tiny hidden cancer cells after stage III colon cancer surgery using a blood test. If the blood test shows tumor DNA, you may get additional treatment to lower the chance of cancer coming back.
Boston, MassachusettsAges 18 years+ - NCT04486352RecruitingPhase 1/Phase 2
Targeted therapy trial for recurrent or persistent endometrial cancer
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
Duarte, CaliforniaAges 18 years+ - NCT04620187RecruitingPhase 2
Study medicine T-DM1 after surgery for HER2-positive salivary cancer
This Phase 2 trial studies T-DM1 given after surgery for salivary gland cancer that is HER2-positive. The goal is to reduce the risk of the cancer coming back by targeting HER2-positive tumor cells.
Atlanta, GeorgiaAges 18 years+ - NCT07600164RecruitingPhase 4
Real-world study of pyrotinib treatment for advanced HER2-positive breast cancer
This study follows patients with advanced breast cancer that has a protein called HER2 to see how well pyrotinib (a targeted drug) works when used in routine clinical practice. You'd be tracked over time to understand how this treatment affects your cancer and quality of life.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04986579RecruitingPhase 2
Scalp cooling to reduce hair loss during breast cancer chemotherapy
This Phase 2 trial tests whether using a scalp-cooling device during chemotherapy can help prevent or lessen hair loss in people with metastatic invasive breast cancer. You would need to be starting a specific chemotherapy plan and be willing to begin scalp cooling with your first treatment.
Boston, MassachusettsAges 18 years+ - NCT04993014RecruitingPhase 2
De-escalating treatment after HER2-positive breast cancer responds
This study looks at whether some people with HER2-positive breast cancer can safely receive less (de-escalated) treatment after they finish chemotherapy plus HER2-targeted drugs before surgery. It specifically focuses on people whose cancer shows a complete response on the surgery pathology report.
São PauloAges 18 years+
Hear when a new Trastuzumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for trastuzumab?
- Yes. Clin2 currently lists 234 recruiting trastuzumab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a trastuzumab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a trastuzumab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.